MediMabBio participated in Cytokines 2025, a leading international conference where researchers and industry experts gather to discuss the latest advances in cytokines, interferons, innate immunity, and immune-mediated diseases.
At the conference, MediMabBio presented a poster titled “Overcoming the Limitations of IL-10 Therapy in Autoimmunity Through a Novel Anti-TIGIT Agonist × IL-10 Fusion Antibody”, highlighting its autoimmune disease candidate MFA031 and its differentiated mechanism of action.
The meeting provided valuable opportunities to engage with global researchers and industry leaders, gain insights into emerging immunology trends, and validate the scientific and therapeutic potential of MFA031. The participation also helped strengthen MediMabBio’s strategy for advancing next-generation immunomodulatory therapies and expanding future collaboration opportunities.